Literature DB >> 2616397

Chronic active hepatitis: a sixteen year survey at a district general hospital.

A R Tanner1, A W Dellipiani.   

Abstract

Over a period of 16 years (1971-87) all cases of chronic active hepatitis (CAH) diagnosed following liver biopsy have been reviewed to assess incidence, aetiology, outcome and response to treatment. North Tees District serves a population of 210,000 and 26 cases were identified (20 female) age range 9-73 years (median 56 years). Incidence remained constant at 1:100,000/year. Twenty cases (77%) had an immune aetiology. Other aetiologies were hepatitis B virus (HBV) infection, alpha-1AT deficiency, non-A non-B hepatitis and a complex multisystem disease. The median follow-up period was 50 months. There were 7 deaths, three unrelated to liver disease. Survival analysis gives an 86% 5-year survival and 56% 10-year survival. Twenty four patients were treated with steroids (and 6 additionally with azathioprine); 15 (63%) were steroid responsive and 9 were non-responsive. In five patients steroids were successfully discontinued but in 10 patients severe symptomatic relapse occurred on steroid reduction below 7.5-10 mg/day. Steroid non-responders were not typical CAH, 5 with predominantly a rise in alkaline phosphatase, one multisystem disease and one HBV positive. Steroid discontinuation was only possible in one third of the patients responding. Eighteen subjects (69%) were cirrhotic at initial biopsy; 9 had follow-up biopsies, 6 were unchanged but three had progressed to cirrhosis despite apparent steroid responsiveness.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2616397      PMCID: PMC2429844          DOI: 10.1136/pgmj.65.768.725

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  14 in total

1.  Controlled trial of prednisone and azathioprine in active chronic hepatitis.

Authors:  I M Murray-Lyon; R B Stern; R Williams
Journal:  Lancet       Date:  1973-04-07       Impact factor: 79.321

2.  Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.

Authors:  R D Soloway; W H Summerskill; A H Baggenstoss; M G Geall; G L Gitnićk; I R Elveback; L J Schoenfield
Journal:  Gastroenterology       Date:  1972-11       Impact factor: 22.682

3.  Controlled prospective trial of corticosteroid therapy in active chronic hepatitis.

Authors:  G C Cook; R Mulligan; S Sherlock
Journal:  Q J Med       Date:  1971-04

4.  Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution.

Authors:  A H Baggenstoss; R D Soloway; W H Summerskill; L R Elveback; L J Schoenfield
Journal:  Hum Pathol       Date:  1972-06       Impact factor: 3.466

5.  Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome.

Authors:  A P Geubel; A H Baggenstoss; W H Summerskill
Journal:  Gastroenterology       Date:  1976-09       Impact factor: 22.682

6.  Chronic active hepatitis: the spectrum of disease.

Authors:  J R Hodges; G H Millward-Sadler; R Wright
Journal:  Lancet       Date:  1982-03-06       Impact factor: 79.321

7.  Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis.

Authors:  J E Hegarty; K T Nouri Aria; B Portmann; A L Eddleston; R Williams
Journal:  Hepatology       Date:  1983 Sep-Oct       Impact factor: 17.425

8.  Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis.

Authors:  A P Kirk; S Jain; S Pocock; H C Thomas; S Sherlock
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

9.  Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis.

Authors:  K C Lam; C L Lai; C Trepo; P C Wu
Journal:  N Engl J Med       Date:  1981-02-12       Impact factor: 91.245

10.  The long-term course of non-A, non-B post-transfusion hepatitis.

Authors:  R L Koretz; O Stone; G L Gitnick
Journal:  Gastroenterology       Date:  1980-11       Impact factor: 22.682

View more
  1 in total

1.  National incidence of autoimmune liver diseases and its relationship with the human development index.

Authors:  Hong-Ying Pan; Yi-Ning Dai; Ji-Na Zheng; Ke-Qing Shi; Sven Van Poucke; Hai Zou; Ming-Hua Zheng
Journal:  Oncotarget       Date:  2016-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.